Article Text

PDF
Clinical science
Metastatic retinoblastoma: single institution experience over two decades
  1. R Cozza1,
  2. M A De Ioris1,
  3. I Ilari1,
  4. R Devito2,
  5. P Fidani1,
  6. L De Sio1,
  7. F Demelas1,
  8. A Romanzo3,
  9. A Donfrancesco1
  1. 1
    Pediatric Oncology Unit, Ospedale Pediatrico Bambino Gesù, Rome, Italy
  2. 2
    Department of Pathology, Ospedale Pediatrico Bambino Gesù, Rome, Italy
  3. 3
    Division of Ophtalmology, Ospedale Pediatrico Bambino Gesù, Rome, Italy
  1. Correspondence to Dr M A De Ioris, Ospedale Pediatrico Bambino Gesù IRCCS, Piazza S Onofrio 4, 00165 Rome, Italy; deioris{at}opbg.net

Abstract

Background: Metastatic spread in retinoblastoma is a rare occurrence in developed countries but still associated with a poor prognosis.

Patients and methods: Medical records of all metastatic retinoblastoma diagnosed during a 20-year period were retrospectively reviewed.

Results: Six patients out of 104 presented a metastatic disease with an incidence at diagnosis of 2%. Three had a metastatic disease at diagnosis, one patient a trilateral retinoblastoma and two a metastatic spread after enucleation. All but one were sporadic retinoblastoma. Central nervous system (CNS) involvement was reported in five patients, while one patient had an intraorbital lesion, and bone and bone marrow spread. Different treatment strategies were administered based on local treatment plus chemotherapy and radiotherapy with or without high-dose chemotherapy. An ifosfamide/carboplatin/etoposide regimen was administered in three patients resulting in a partial response. Out of six patients, four died, and two patients are alive at 60 and 63 months from diagnosis. Both children with a long follow-up were treated with high-dose chemotherapy. All but one of the patients with CNS involvement died; the survivor was a patient with pineal involvement.

Conclusion: This retrospective review confirms a curable strategy based on local treatment and conventional plus high-dose chemotherapy. Patients with CNS involvement remain incurable.

Statistics from Altmetric.com

Footnotes

  • Funding Girasole Onlus (MADI and FD).

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • See Editorial, p 1129

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.